By Chris Wack


SeqLL Inc. said Tuesday it has entered into a two-year cooperative research and development agreement with the Federal Bureau of Investigation.

Under the agreement, SeqLL and the FBI Laboratory Division will seek to evaluate and determine the forensic capabilities of direct RNA sequencing using SeqLL's True Single Molecule Sequencing platform.

The FBI and SeqLL aim to produce an assay for forensic body fluid identification, without compromising traditional DNA sequence analysis.

SeqLL shares were up 95% to $1.05 in premarket trading.


Write to Chris Wack at


(END) Dow Jones Newswires

February 07, 2023 08:07 ET (13:07 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.